Australis Capital Inc.

CNSX:AUSA Stock Report

Market Cap: CA$8.7m

Australis Capital Valuation

Is AUSA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AUSA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AUSA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AUSA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AUSA?

Key metric: As AUSA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AUSA. This is calculated by dividing AUSA's market cap by their current revenue.
What is AUSA's PS Ratio?
PS Ratio0.9x
SalesCA$9.47m
Market CapCA$8.75m

Price to Sales Ratio vs Peers

How does AUSA's PS Ratio compare to its peers?

The above table shows the PS ratio for AUSA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average20x
PWR Captiva Verde Wellness
51.2xn/aCA$9.0m
AION Aion Therapeutic
9xn/aCA$7.3m
GLOW Glow Lifetech
19.4xn/aCA$6.7m
HERB Herbal Dispatch
0.5xn/aCA$4.5m
AUSA Australis Capital
0.9xn/aCA$8.7m

Price-To-Sales vs Peers: AUSA is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (2.8x).

Price to Sales Ratio vs Industry

How does AUSA's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

25 CompaniesPrice / SalesEstimated GrowthMarket Cap
AYR.A Ayr Wellness
0.2x2.5%US$79.88m
IAN iAnthus Capital Holdings
0.1xn/aUS$47.73m
TIUM.U Cansortium
0.2xn/aUS$25.68m
ACRG.A.U Acreage Holdings
0.007xn/aUS$17.58m
AUSA 0.9xIndustry Avg. 0.7xNo. of Companies25PS012345+
25 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: AUSA is good value based on its Price-To-Sales Ratio (0.9x) compared to the Canadian Pharmaceuticals industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is AUSA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AUSA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.9x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate AUSA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Medexus Pharmaceuticals

CA$58.7m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.38

7D

12.8%

1Y

60.8%

Verano Holdings

CA$722.2m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$1.98

7D

-17.2%

1Y

-65.9%

Cresco Labs

CA$525.4m

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.

CL

CA$1.67

7D

-8.2%

1Y

-27.7%